Black Hawk SPAC loses $25M to redemptions ahead of Vesicor merger
What's the deal? Black Hawk Acquisition CorporationDealroom has a profile for this one. Try Dealroom → said holders of 2,089,162 Class A ordinary shares exercised redemption rights ahead of its merger with Vesicor TherapeuticsDealroom has a profile for this one. Try Dealroom →, triggering payments of about $25.15 million. The special purpose acquisition company (SPAC) now expects roughly 2.06 million Class A shares outstanding, with an estimated $420,377 left in its trust account.
What's the endgame? The two first agreed to combine on April 26, 2025. Once the deal closes, the merged business is set to trade on the Nasdaq under the ticker "VESI."
What each side brings: Vesicor is a preclinical-stage biotech developing p53-based cancer therapeutics delivered through precision-engineered microvesicles. Its lead candidate, ecm-RV/p53, uses a non-viral platform to carry p53 mRNA into cancer cells and aims to restore tumour suppression in advanced solid tumours. Black Hawk is a blank-cheque firm targeting the healthcare sector.
What could go wrong? The heavy redemptions leave the trust account with just over $420,000, a thin cushion for a drug developer years away from commercial products. Preclinical biotechs face long, costly paths to approval and typically need substantial outside funding to advance trials.
The signal: Large redemptions have become a familiar feature of SPAC deals, as investors cash out rather than back the combined company. For Vesicor, the merger offers a public listing; the open question is how much capital survives to fund its research.
Read more: benzinga.com
Image credit: Generated with Gemini
